Un-Answered Queries Towards JQ1 Unveiled

1m and 5m for patients in PD; respectively. Seventeen patients (17%) relapsed. Median time from RIC-allo to relapse was 6?months (range, 2�C57) and 46 patients (44%) died. Causes of death were related to toxicity in 29 cases, lymphoma progression in 9 patients and other causes in six patients (data missing?=?2). Conclusion: Our ongoing analysis shows that incidence of relapse after RIC-allo remains high for MCL patients who have previously relapsed after ASCT. As expected, patients in CR at time of RIC-allo experience a longer PFS duration, underlying that new salvage therapies are highly warranted prior to RIC-allo. http://www.selleckchem.com/products/jq1.html 113 TARGETING THE IRF4/MYC AXIS IN BORTEZOMIB-RESISTANT MANTLE CELL LYMPHOMA WITH LENALIDOMIDE AND BET BROMODOMAIN INHIBITION A. Moros,1 V. Rodriguez,1 I. Saborit-Villarroya,1 A. Montraveta,1 A. Martinez,2 E. Campo,2 P. Perez-Galan,1 D. Colomer,2 G. Roue,1 1Hemato-Oncology, IDIBAPS, Barcelona, Spain,2Hematopathology Unit, Hospital Clinic, Barcelona, Spain Introduction: Despite the promising introduction of the proteasome inhibitor bortezomib (bz) in the treatment of mantle cell lymphoma (MCL), not all the patients respond and relapses frequently occur. Our aim was to unravel the intratumoural and environmental factors involved in bz resistance in preclinical models of MCL. Methods: A set of MCL cell lines http://www.selleckchem.com/products/Rapamycin.html was engrafted onto immunodeficient mice, followed by gene expression profiling and immunohistochemical (IHC) analyses of representative http://www.selleck.cn/products/AP24534.html tumours. The immunomoduladory drug lenalidomide was then applied to MCL cultures and MCL tumour bearing mice, either alone or in combination with bz or with the BET bromodomain inhibitor CPI-267203. Response to drugs and drug combinations was analysed by in vivo imaging, flow cytometry, western blot, antibody array, real-time PCR, immunofluorescence and IHC. Results: We observed an increased tumourigenicity of bz-resistant MCL cell lines in vivo, that was associated with plasmacytic differentiation, including up-regulation of IRF4 and CD38 and secretion of CCL3. As lenalidomide has been shown to modulate IRF4 expression in various B-cell malignancies, we assessed its activity in in vitro and in vivo settings. In vitro, lenalidomide as single agent was found to exert antitumour activity in 4/11 MCL cell lines, corresponding to those cells with either primary or acquired resistance to bz. Lenalidomide-treated cells showed decreased MYC expression, increased cytosolic p27,KIP1 amounts and caspase-dependent apoptosis. Accordingly, mice bearing bz-resistant tumours and treated for 3 weeks with a lenalidomide regimen of 10�C50?mg/kg/day, showed a 30 to 45% reduction in tumour burden when compared with vehicle-treated mice (p?